Dataset from Phase 1 Randomized, Blinded, Placebo-Controlled Study of Single Ascending Doses of BIIB063 in Healthy Volunteers
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/00007208
下载链接
链接失效反馈官方服务：
资源简介：
The primary objective of the study is to evaluate the safety and tolerability of single
ascending intravenous (IV) doses and a single subcutaneous (SC) dose of BIIB063 in healthy
volunteers. The secondary objectives of the study are to estimate the PK parameters of single
ascending IV doses of BIIB063; to estimate the PK parameters and absolute bioavailability (F)
of a single SC dose of BIIB063; and to evaluate the immunogenicity of single ascending doses
of BIIB063.
创建时间：
2025-07-07
